{
    "id": "620c27e93a8413c653000006",
    "question": "Is METTL1 overexpression associated with better patient survival?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "After analyzing the provided documents, I was unable to find any information that directly addresses whether METTL1 overexpression is associated with better patient survival. However, I can tell you that MET (hepatocyte growth factor receptor) overexpression is associated with a poorer prognosis in some cancers, such as papillary renal cell carcinoma. But, METTL1 is a gene that encodes a component of the N6-methyltransferase complex, which is involved in the regulation of mRNA stability and translation. While there is no direct information on METTL1 overexpression in cancer prognosis, I can suggest that it is possible that alterations in the expression levels of METTL1 could have an impact on cancer biology, potentially influencing patient survival. However, without specific information on METTL1 overexpression in cancer patients, it is difficult to provide a definitive answer. Therefore, my output is: {\"step_by_step_thinking\": \"After analyzing the provided documents, I was unable to find any information that directly addresses whether METTL1 overexpression is associated with better patient survival. However, I can suggest that it is possible that alterations in the expression levels of METTL1 could have an impact on cancer biology, potentially influencing patient survival. Without specific information on METTL1 overexpression in cancer patients, it is difficult to provide a definitive answer.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_8486",
            "title": "InternalMed_Harrison",
            "content": "In addition to gene mutations, deregulation of the expression levels of coding genes and of short noncoding RNAs (microRNAs) have been reported to provide prognostic information (Table 132-3). Overexpression of genes such as brain and acute leukemia, cytoplasmic (BAALC), v-ets avian erythroblastosis virus E26 oncogene homologue (avian) (ERG), meningioma (disrupted in balanced translocation) 1 (MN1), and MDS1 and EVI1 complex locus (MECOM, also known as EVI1) have been found to be predictive for poor outcome, especially in CN-AML. Similarly, deregulated expression levels of microRNAs, naturally occurring noncoding RNAs that have been shown to regulate the expression of proteins involved in hematopoietic differentiation and survival pathways by degradation or translation inhibition of target coding RNAs, have been associated with prognosis in AML. Overexpression of miR-155 and miR-3151 has been found to affect outcome adversely in CN-AML, whereas overexpression of miR-181a predicts a"
        },
        {
            "id": "InternalMed_Harrison_6297",
            "title": "InternalMed_Harrison",
            "content": "While apoptotic mechanisms are important in regulating cellular proliferation and the behavior of tumor cells in vitro, in vivo it is unclear whether all of the actions of chemotherapeutic agents to cause cell death can be attributed to apoptotic mechanisms. However, changes in molecules that regulate apoptosis are correlated with clinical outcomes (e.g., bcl2 overexpression in certain lymphomas conveys poor prognosis; proapoptotic bax expression is associated with a better outcome after chemotherapy for ovarian carcinoma). A better understanding of the relationship of cell death and cell survival mechanisms is needed."
        },
        {
            "id": "Neurology_Adams_5216",
            "title": "Neurology_Adams",
            "content": "greatly reduce the period of survival. Acquired genetic alterations in the tumor cells that have prognostic influence have been summarized earlier. A novel inhibitor of the abnormal hedgehog pathway in medulloblastoma cells had a marked therapeutic effect in one adult patient (Rudin et al)."
        },
        {
            "id": "Cell_Biology_Alberts_5150",
            "title": "Cell_Biology_Alberts",
            "content": "18\u20132 Mammalian cells that do not have cytochrome c should be resistant to apoptosis induced by DNA damage. Discuss the following problems. 18\u20133 One important role of Fas and Fas ligand is to mediate the elimination of tumor cells by killer lymphocytes. In a study of 35 primary lung and colon tumors, half the tumors were found to have amplified and overexpressed a gene for a secreted protein that binds to Fas ligand. How do you suppose that overexpression of this protein might contribute to the survival of these tumor cells? Explain your reasoning."
        },
        {
            "id": "Cell_Biology_Alberts_5654",
            "title": "Cell_Biology_Alberts",
            "content": "in some cases, have declined significantly (Figure 20\u201339). Survival rates, moreover, have improved. Thirty years ago, less than 50% of patients lived more than five years from the time of diagnosis; now, more than two-thirds do so."
        },
        {
            "id": "Pathology_Robbins_3513",
            "title": "Pathology_Robbins",
            "content": "genetic analysis shows activating mutations of MET in the germ line, along with increased gene dosage in the cancers. Activating mutations of the MET gene also are found in a subset of patients with sporadic forms of papillary renal cell carcinoma."
        },
        {
            "id": "InternalMed_Harrison_8483",
            "title": "InternalMed_Harrison",
            "content": "to be associated with outcome in multivariable analyses independently from other prognostic factors. However, for some of them, the prognostic impact (e.g., TET2 mutations) or the type (adverse vs favorable) of prognostic impact (e.g., IDH1, IDH2) has been found in the majority, but not in all, of the reported studies. An independent prognostic impact remains to be determined for mutated genes that are either associated primarily with unfavorable"
        },
        {
            "id": "InternalMed_Harrison_6798",
            "title": "InternalMed_Harrison",
            "content": "in patients with good performance status. In addition, economic analysis has found chemotherapy to be cost-effective palliation for stage IV NSCLC. However, the use of chemotherapy for NSCLC requires clinical experience and careful judgment to balance potential benefits and toxicities. Of note, the early application of palliative care in conjunction with chemotherapy is associated with improved survival and a better quality of life."
        },
        {
            "id": "InternalMed_Harrison_6037",
            "title": "InternalMed_Harrison",
            "content": "activation by translocation, although not universal, appears to play an important role in malignant progression. In addition to transcription factors and signal transduction molecules, translocation may result in the overexpression of cell cycle"
        },
        {
            "id": "InternalMed_Harrison_25431",
            "title": "InternalMed_Harrison",
            "content": "of PAH is strongly associated with mortality, and SSc patients who had a mean pulmonary arterial pressure \u226545 mmHg had a 33% 3-year survival. The advent of ACE inhibitors in scleroderma renal crisis had a dramatic impact on survival, increasing from <10% at 1 year in the pre\u2013ACE inhibitor era to >70% 3-year survival at the present time. Moreover, 10-year survival inSSc has improvedfrom<60%inthe 1970s to >66\u201378%inthe 1990s, a trend that reflects both earlier detection and better management of complications."
        },
        {
            "id": "InternalMed_Harrison_8814",
            "title": "InternalMed_Harrison",
            "content": "The molecular pathogenesis of aCML is incompletely understood; about one-fourth of the patients express SETBP1 mutations, which are, however, also found in several other myeloid malignancies, including CNL and chronic myelomonocytic leukemia. SETBP1 mutations in aCML were prognostically detrimental and mostly located between codons 858 and 871; similar mutations are seen with Schinzel-Giedion syndrome (a congenital disease with severe developmental delay and various physical stigmata including midface retraction, large forehead, and macroglossia)."
        },
        {
            "id": "Neurology_Adams_5218",
            "title": "Neurology_Adams",
            "content": "In keeping with the genetic determinants of prognosis in this broad class of tumors, a loss of heterozygosity of certain sites on chromosomes 1 and 11 has been associated with somewhat poorer outcomes by Attiyeh and colleagues. MYCN amplification or overexpression is a poor prognostic factor, as it is in medulloblastoma. Various acquired chromosomal deletions and gains may also have predictive importance. More provocative are findings that suggest the emergence of an aggressive tumor based on polymorphisms in chromosome 6p. Maris has provided a review of the interesting genetic aspects of the tumor. Several staging systems have evolved for neuroblastoma and The Children\u2019s Oncology Group has produced a risk-based system that includes the status of chromosomal changes (17q, 1p, 11q), but these approaches are under frequent revision."
        },
        {
            "id": "InternalMed_Harrison_8435",
            "title": "InternalMed_Harrison",
            "content": "Note: The Dynamic International Prognostic Scoring System (DIPSS) was developed to determine if the International Prognostic Scoring System (IPSS) risk factors identified as important for survival at the time of primary myelofibrosis (PMF) diagnosis could also be used for risk stratification following their acquisition during the course of the disease. One point is assigned to each risk factor for IPSS scoring. For DIPSS, the same is true, but age >65 years, anemia, blood blasts, and constitutional symptoms are assigned 2 points each. The DIPSS Plus scoring system represents recognition that the addition of unfavorable karyotype, thrombocytopenia, and transfusion dependence improved the DIPSS risk stratification system for which additional points are assigned (Table 131-5). More recent studies suggest that mutational analysis of the ASXL1, EZH2, SRSF2, and IDH1/2 genes further improves risk stratification for survival and leukemic transformation (Leukemia 27:1861, 2013)."
        },
        {
            "id": "InternalMed_Harrison_6229",
            "title": "InternalMed_Harrison",
            "content": "The explosion of information on tumor cell biology, metastasis, and tumor-host interactions (including angiogenesis and immune evasion by tumors) has ushered in a new era of rational targeted therapy for cancer. Furthermore, it has become clear that specific molecular factors detected in individual tumors (specific gene mutations, gene-expression profiles, microRNA expression, overexpression of specific proteins) can be used to tailor therapy and maximize antitumor effects. Robert G. Fenton contributed to this chapter in prior editions, and important material from those prior chapters has been included here."
        },
        {
            "id": "InternalMed_Harrison_8487",
            "title": "InternalMed_Harrison",
            "content": "coding RNAs, have been associated with prognosis in AML. Overexpression of miR-155 and miR-3151 has been found to affect outcome adversely in CN-AML, whereas overexpression of miR-181a predicts a favorable outcome both in CN-AML and cytogenetically abnormal AML."
        },
        {
            "id": "Pathology_Robbins_5184",
            "title": "Pathology_Robbins",
            "content": "Wnt pathway activation, most commonly associated with gain of function mutations in the gene for \u03b2-catenin; these have the most favorable prognosis of all of the genetic subtypes and are commonly classic-type tumors. Hedgehog pathway activation, most commonly associated with loss of function mutations in PTCH1, a negative regulator of the Hedgehog; these tumors have an intermediate prognosis, but the concomitant presence of TP53 mutation confers a very poor prognosis. MYC overexpression, due to MYC amplification as well as other changes that result in increased expression; these tumors have the poorest prognosis. Clinical trials are ongoing that seek to tailor therapy targeted to molecular alterations, with the goal of avoiding radiation therapy when possible."
        },
        {
            "id": "InternalMed_Harrison_8586",
            "title": "InternalMed_Harrison",
            "content": "Pretreatment prognostic factors and prognostic models have lost much of their clinical relevance to define prognosis and to select different therapies. However TKI-associated therapeutic responses have gained major clinical relevance and dictate appropriate and careful monitoring of patients to optimize their treatment."
        },
        {
            "id": "Surgery_Schwartz_2350",
            "title": "Surgery_Schwartz",
            "content": "PM 350BASIC CONSIDERATIONSPART Iwith response to certain agents. It is likely that in the near future all tumors can be tested and treatments individualized. Patients who will respond to conventional therapies can be treated with these regimens, whereas patients who will not respond will not, which spares them the toxicity. Instead, the latter patients can be offered novel therapies. Furthermore, with the advent of effec-tive immune-based therapies, it is likely that patients may be given treatments that can specifically target the alterations driv-ing tumor growth in combination with drugs that can enhance the anticancer immune response. Patients can be genotyped for critical alleles that may affect drug metabolism and thus, may influence the efficacy as well as the side effects of the drugs given. Finally, stratification of patients by gene expression pro-file for prognosis may assist in determining which patients are at higher risk of relapse so that patients whose tumors have less"
        },
        {
            "id": "Surgery_Schwartz_2296",
            "title": "Surgery_Schwartz",
            "content": "group. The hazard ratio for tumor progression in the vemu-rafenib group was 0.26 (95% CI, 0.20\u20130.33; P<0.001). The estimated median progression-free survival was 5.3 months in the vemurafenib group and 1.6 months in the dacarbazine group. This trial highlights the fact that in at least some tumor types targeted therapies that inhibit a genomic alteration that is a driver is likely to be more effective than an unselected thera-peutic option.Sequencing of the human genome has revealed approxi-mately 500 protein kinases. Several tyrosine kinases have been shown to have oncogenic properties and many other protein kinases have been shown to be aberrantly activated in cancer cells.93 Therefore, protein kinases involved in these aberrantly activated pathways are being aggressively pursued in molecular therapeutics. Potential targets like HER2 can be targeted via dif-ferent strategies, such as transcriptional downregulation, targeting of mRNA, RNA inhibition, antisense strategies, direct"
        },
        {
            "id": "Pathology_Robbins_3512",
            "title": "Pathology_Robbins",
            "content": "Papillary renal cell carcinomas account for 10% to 15% of all renal cancers and are defined in part by their papillary growth pattern. These neoplasms are frequently multifocal and bilateral and appear as early-stage tumors. Like clear cell carcinomas, they occur in familial and sporadic forms, but unlike these neoplasms, papillary renal cancers are not associated with abnormalities of chromosome 3. The culprit in most cases of hereditary papillary renal cell cancers is the MET proto-oncogene, located on chromosome 7q. The MET gene encodes a tyrosine kinase receptor for hepatocyte growth factor. The increased dosage of the MET gene due to duplications of chromosome 7 seems to spur abnormal growth in the proximal tubular epithelial cell precursors of papillary carcinomas. In familial cases, genetic analysis shows activating mutations of MET in the germ line, along with increased gene dosage in the cancers. Activating mutations of the MET gene also are found in a subset of patients with"
        },
        {
            "id": "InternalMed_Harrison_8822",
            "title": "InternalMed_Harrison",
            "content": "A French study incorporated ASXL1 mutational status in 312 CMML patients. In a multivariable model, independent predictors of poor survival were WBC >15 \u00d7 109/L (3 points), ASXL1 mutations (2 points), age >65 years (2 points), platelet count <100,000/mL (2 points), and hemoglobin <10 g/dL in females and <11 g/dL in males (2 points). This model stratified patients into three groups: low (0\u20134 points), intermediate (5\u20137 points), and high risk (8\u201312 points), with median survival times of not reached, 38.5 months, and 14.4 months, respectively."
        },
        {
            "id": "Surgery_Schwartz_3922",
            "title": "Surgery_Schwartz",
            "content": "and distant recurrence (98.7%) and very good overall survival at 5 years (98%) with endocrine therapy alone without chemotherapy.204 This study has ran-domly assigned patients with an intermediate recurrence score (11 to 25) to endocrine therapy alone or to chemotherapy fol-lowed by endocrine therapy.Additionally, retrospective analysis has shown that the 21-gene recurrence score can be used in postmenopausal patients with ER-positive tumors and 1 to 3 involved axillary lymph nodes to predict the benefit of chemotherapy in addition to endocrine therapy.205 Knowledge of the recurrence score has been shown to alter treatment recommendations by oncologists, and patients likewise change their decision to undergo treatment based on the risk of recurrence.206 The MammaPrint assay uses a 70-gene expression profile to assess the risk of distant metas-tasis. Mammaprint is FDA approved for use in stage-1 or stage-2, node negative, ER-positive or ER-negative breast cancers to identify patients"
        },
        {
            "id": "Surgery_Schwartz_2234",
            "title": "Surgery_Schwartz",
            "content": "RS scores in whom the role of chemotherapy is unclear. Several other multigene predictors for breast cancer are available including MammaPrint, a gene expression profiling platform assessing a Brunicardi_Ch10_p0305-p0354.indd 33422/02/19 2:14 PM 335ONCOLOGYCHAPTER 1070-gene transcriptional signature.115 This assay was approved by the Food and Drug Administration (FDA) in February 2007. The usefulness of this assay in making therapy-related decisions was tested prospectively in a large-scale study, the Microarray in Node-Negative Disease May Avoid Chemotherapy (MIND-ACT) trial. Among women with early-stage breast cancer who were determined to be at high clinical risk and low genomic risk for cancer recurrence, the receipt of no adjuvant chemotherapy on the basis of the 70-gene signature result led to a 5-year metas-tasis survival rate that was 1.5% lower than the rate in patients who had received chemotherapy. In light of these findings, 45% of women with breast cancer who are"
        },
        {
            "id": "Surgery_Schwartz_2351",
            "title": "Surgery_Schwartz",
            "content": "given. Finally, stratification of patients by gene expression pro-file for prognosis may assist in determining which patients are at higher risk of relapse so that patients whose tumors have less aggressive biologic characteristics can be spared further therapy.REFERENCESEntries highlighted in bright blue are key references. 1. Siegel R, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30. 2. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-1674. 3. Siegel R, Miller KD, Jemal A. Cancer statistics, 2016. CA: Cancer J Clin. 2016;66:7-30. 4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM; International Agency for Research on Cancer. GLO-BOCAN 2008 v2.0, Cancer incidence and mortality world-wide. Available at: https://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php. Accessed July 1, 2018. 5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,"
        },
        {
            "id": "Surgery_Schwartz_7549",
            "title": "Surgery_Schwartz",
            "content": "epidermal growth factor receptor-2 (HER2) was reported in patients with gastric cancer. In breast cancer, overexpression of HER2 has been reported in 15% to 25% of cases, and it is well recognized as an unfavorable prognostic factor. The development of molecular targeted agents such as trastuzumab has improved the survival of HER2-positive patients. Likewise, in gastric cancer, HER2 overexpression has been reported in 13% to 30% of patients. HER2 targeting with trastuzumab resulted in improved survival in patients with stage IV gastric cancer, and immunohistochem-istry (IHC) staining for HER2 should be performed in recurrent or metastatic cases.152 Expression of other growth receptors in gastric cancer have been characterized as well, including HER1 (epidermal growth factor rector) and HER3. The latter is associ-ated with poor prognosis, but efforts to target these receptors for therapeutic benefit are still exploratory.153Pathologic Staging Ultimately, prognosis is related to"
        },
        {
            "id": "InternalMed_Harrison_7024",
            "title": "InternalMed_Harrison",
            "content": "Efforts to use gene expression profiles to identify patients at risk of recurrence or those particularly likely to benefit from adjuvant therapy have not yet yielded practice-changing results. Despite a burgeoning literature examining a host of prognostic factors, pathologic stage at diagnosis remains the best predictor of long-term prognosis. Patients with lymphovascular invasion and high preoperative CEA levels are likely to have a more aggressive clinical course."
        },
        {
            "id": "InternalMed_Harrison_7600",
            "title": "InternalMed_Harrison",
            "content": "With this regimen, median survival is increased to 14.6 months compared to only 12 months with RT alone, and 2-year survival is increased to 27%, compared to 10% with RT alone. Patients whose tumor contains the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) are relatively resistant to temozolomide and have a worse prognosis compared to those whose tumors contain low levels of MGMT as a result of silencing of the MGMT gene by promoter hypermethylation. Implantation of biodegradable polymers containing the chemotherapeutic agent carmustine into the tumor bed after resection of the tumor also produces a modest improvement in survival."
        },
        {
            "id": "Gynecology_Novak_6663",
            "title": "Gynecology_Novak",
            "content": "Figure 35.6 Surgical management of patients with stage I\u2013II endometrial carcinoma. p16 (45%) and overexpression and gene amplification of HER2/neu oncogene (45% and 70%, respectively) (232,236,237). HER-2/neu overexpression is related to diminished, progression-free survival (238\u2013240). E-cadherin, an oncogene responsible for cell-to-cell adhesion that seems to play a critical role in initiation and progression of endometrial neoplasia, is absent or reduced in 62% to 87% of cases. Loss of E-cadherin is often associated with advanced stage and LOH in both serous and clear cell carcinomas (214,241,242)."
        },
        {
            "id": "Immunology_Janeway_1650",
            "title": "Immunology_Janeway",
            "content": "A. ___ Kit B. ___ B-cell receptor C. ___ fLT3 D. ___ TGf-\u03b2 receptor 7.3 Short Answer: how can scaffolds and adaptors modulate signaling responses if they have no intrinsic enzymatic activity? 7.4 Multiple Choice: Which of the following alterations would result in increased activity of Ras (one or more may apply): A. a mutation in Ras that enhances its GTpase activity B. overexpression of Gefs C. depletion of GTp in the cytoplasm D. overexpression of Gaps"
        },
        {
            "id": "Surgery_Schwartz_2352",
            "title": "Surgery_Schwartz",
            "content": "and mortality world-wide. Available at: https://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php. Accessed July 1, 2018. 5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. 6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. 7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next gen-eration. Cell. 2011;144:646-674. 8. Pelengaris S, Khan M, Evan G. c-MYC: more than just a mat-ter of life and death. Nat Rev Cancer. 2002;2:764-776. 9. Li C-J, Zhang, X, Fan G-W. Updates in colorectal cancer stem cell research. J Cancer Res Ther. 2014;10:233-239. 10. Kastan M, Skapek S. Molecular biology of cancer: the cell cycle. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. 11. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neopla-sia."
        },
        {
            "id": "InternalMed_Harrison_6154",
            "title": "InternalMed_Harrison",
            "content": "Epigenetic gene regulation can also occur via microRNAs or long non-coding RNAs (lncRNAs). MicroRNAs are short (average 22 nucleotides in length) RNA molecules that silence gene expression after transcription by binding and inhibiting the translation or promoting the degradation of mRNA transcripts. It is estimated that more than 1000 microRNAs are encoded in the human genome. Each tissue has a distinctive repertoire of microRNA expression, and this pattern is altered in specific ways in cancers. However, specific correlations between microRNA expression and tumor biology and clinical behavior are just now emerging. Therapies targeting microRNAs are not currently at hand but represent a novel area of treatment development. lncRNAs are longer than 200 nucleotides and compose the largest group of noncoding RNAs. Some of them have been shown to play important roles in gene regulation. The potential for altering these RNAs for therapeutic benefit is an area of active investigation,"
        },
        {
            "id": "InternalMed_Harrison_8739",
            "title": "InternalMed_Harrison",
            "content": "Treatment regimens appropriate for other aggressive lymphomas, such as diffuse large B-cell lymphoma, should be used in patients with anaplastic large T/null-cell lymphoma, with the exception that the B-cell\u2013specific antibody, rituximab, is omitted. Surprisingly, given the anaplastic appearance, this disorder has the best survival rate of any aggressive lymphoma. The 5-year survival is >75%. While traditional prognostic factors such as the IPI predict treatment outcome, overexpression of the ALK protein is an important prognostic factor, with patients overexpressing this protein having a superior treatment outcome. The ALK inhibitor crizotinib appears highly active as well. In addition, the CD30 immunotoxin, brentuximab vedotin, is active in the disease."
        }
    ],
    "scores": [
        0.028263523791732276,
        0.026240859380055652,
        0.018337006611901425,
        0.01796550622804216,
        0.01715542521994135,
        0.01677805625174046,
        0.01655982905982906,
        0.016214449166394244,
        0.016173348320219806,
        0.015765765765765764,
        0.01550751879699248,
        0.015165441176470588,
        0.014826839826839827,
        0.014675841307386302,
        0.014664664664664664,
        0.014585883312933496,
        0.014510104396130638,
        0.014012303485987697,
        0.013859020310633213,
        0.0137731919727376,
        0.012190603231065657,
        0.010944976076555025,
        0.010840188014101058,
        0.009900990099009901,
        0.00980392156862745,
        0.00980392156862745,
        0.00980392156862745,
        0.009708737864077669,
        0.009708737864077669,
        0.009708737864077669,
        0.009708737864077669,
        0.009615384615384616
    ]
}